TW201141487A - Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and HMG-CoA reductase inhibitor - Google Patents
Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and HMG-CoA reductase inhibitor Download PDFInfo
- Publication number
- TW201141487A TW201141487A TW100103931A TW100103931A TW201141487A TW 201141487 A TW201141487 A TW 201141487A TW 100103931 A TW100103931 A TW 100103931A TW 100103931 A TW100103931 A TW 100103931A TW 201141487 A TW201141487 A TW 201141487A
- Authority
- TW
- Taiwan
- Prior art keywords
- aspirin
- hmg
- formulation
- coa reductase
- composite formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100009636A KR101193493B1 (ko) | 2010-02-02 | 2010-02-02 | 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 HMG?CoA 환원효소 억제제를 포함하는 복합제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201141487A true TW201141487A (en) | 2011-12-01 |
Family
ID=44355918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100103931A TW201141487A (en) | 2010-02-02 | 2011-02-01 | Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and HMG-CoA reductase inhibitor |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120301549A1 (ko) |
EP (1) | EP2531199A4 (ko) |
JP (1) | JP2013518873A (ko) |
KR (1) | KR101193493B1 (ko) |
CN (1) | CN102740857A (ko) |
AR (1) | AR080023A1 (ko) |
TW (1) | TW201141487A (ko) |
WO (1) | WO2011096665A2 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201005325A2 (tr) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
WO2018135932A2 (ko) * | 2017-01-23 | 2018-07-26 | 동화약품주식회사 | Hmg-coa 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제 |
WO2023204397A1 (ko) * | 2022-04-19 | 2023-10-26 | 한미약품 주식회사 | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
KR100646576B1 (ko) * | 2005-02-15 | 2006-11-23 | 한국유나이티드제약 주식회사 | 고지혈증 환자의 동맥경화증 예방을 위한 에이치엠지이-씨오에이 환원효소 저해제 및 장용코팅된 아스피린을 함유하는 복합 펠렛 |
WO2009022821A2 (en) * | 2007-08-13 | 2009-02-19 | Hanall Pharmaceutical Company. Ltd | Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
KR20090030452A (ko) * | 2007-09-20 | 2009-03-25 | 한미약품 주식회사 | HMG-CoA 환원효소 억제제와 아스피린을 함유하는복합제제 |
GB2460915B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
-
2010
- 2010-02-02 KR KR1020100009636A patent/KR101193493B1/ko not_active IP Right Cessation
-
2011
- 2011-01-26 JP JP2012551908A patent/JP2013518873A/ja active Pending
- 2011-01-26 WO PCT/KR2011/000541 patent/WO2011096665A2/en active Application Filing
- 2011-01-26 CN CN2011800078123A patent/CN102740857A/zh active Pending
- 2011-01-26 US US13/576,585 patent/US20120301549A1/en not_active Abandoned
- 2011-01-26 EP EP11739961.8A patent/EP2531199A4/en not_active Withdrawn
- 2011-01-26 AR ARP110100246A patent/AR080023A1/es unknown
- 2011-02-01 TW TW100103931A patent/TW201141487A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN102740857A (zh) | 2012-10-17 |
KR101193493B1 (ko) | 2012-10-22 |
JP2013518873A (ja) | 2013-05-23 |
EP2531199A4 (en) | 2013-07-10 |
EP2531199A2 (en) | 2012-12-12 |
US20120301549A1 (en) | 2012-11-29 |
KR20110090060A (ko) | 2011-08-10 |
WO2011096665A2 (en) | 2011-08-11 |
WO2011096665A3 (en) | 2012-01-05 |
AR080023A1 (es) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021282393B2 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
TWI571271B (zh) | 包含ω-3脂肪酸酯及HMG-CoA還原酶抑制劑之口服複合組成物 | |
RU2504362C2 (ru) | Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты | |
KR101298788B1 (ko) | 안정성이 개선된 복합제제 | |
JP2008526732A (ja) | 3−ヒドロキシ−3−メチルグルタリル補酵素a還元酵素阻害剤と高血圧治療剤との複合製剤、及びその製造方法 | |
JP2009527468A (ja) | タイトジャンクション・エフェクター用製剤 | |
TW201141487A (en) | Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and HMG-CoA reductase inhibitor | |
TW201442742A (zh) | 祛鐵斯若(deferasirox)之口服配方 | |
MX2010010479A (es) | Capsula para la prevencion de enfermedades cardiovasculares. | |
TWI710379B (zh) | 錠劑 | |
JP2007522203A5 (ko) | ||
JP2009521526A (ja) | カンシル酸アムロジピン及びシンバスタチンを含む複合製剤及びその製造方法 | |
WO2018065826A1 (en) | Multilayer beads for pharmaceutical use | |
US20130243872A1 (en) | Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin | |
JP2005538097A (ja) | Hmg−coaレダクターゼインヒビターを含む組成物 | |
US20060165788A1 (en) | Lercanidipine pH dependent pulsatile release compositions | |
SA515370243B1 (ar) | صيغة تعطى عن طريق الفم لعلاج الأمراض القلبية الوعائية | |
WO2009065130A2 (en) | Modified release formulations of diltiazem | |
KR102139346B1 (ko) | HMG-CoA 환원효소 억제제 및 클로피도그렐을 포함하는 복합제제 | |
US20070218134A1 (en) | Compositions Comprising Organic Compounds | |
KR20090030452A (ko) | HMG-CoA 환원효소 억제제와 아스피린을 함유하는복합제제 | |
NZ537408A (en) | Microcapsules for the delayed, controlled release of perindopril | |
WO2007120136A1 (en) | Lercanidipine ph dependent pulsatile release compositions | |
AU2005256173A1 (en) | Composition and method for treatment and prevention of atherosclerosis | |
WO2007049587A1 (ja) | 腸溶性製剤 |